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Protein interactionHepatitis B virus (HBV) X protein (HBx) is a key player in HBV replication as well as HBV-induced hepatocel-
lular carcinoma (HCC). However, the pathogenesis of HBV infection and the mechanisms of host–virus inter-
actions are still elusive. In this study, a combination of afﬁnity puriﬁcation and mass spectrometry was
applied to identify the host factors interacting with HBx in hepatoma cells. Thirteen proteins were identiﬁed
as HBx binding partners. Among them, we ﬁrst focused on determining the functional signiﬁcance of the in-
teraction between HBx and hepatocystin. A physical interaction between HBx and hepatocystin was con-
ﬁrmed by co-immunoprecipitation and Western blotting. Immunocytochemistry demonstrated that HBx
and hepatocystin colocalized in the hepatoma cells. Domain mapping of both proteins revealed that the
HBx C-terminus (amino acids 110–154) was responsible for binding to the mannose 6-phosphate receptor
homology domain (amino acids, 419–525) of hepatocystin. Using translation and proteasome inhibitors,
we found that hepatocystin overexpression accelerated HBx degradation via a ubiquitin-independent
proteasome pathway. We demonstrated that this effect was mediated by an interaction between both pro-
teins using a HBx deletion mutant. Hepatocystin overexpression signiﬁcantly inhibited HBV DNA replication
and expression of HBs antigen concomitant with HBx degradation. Using the hepatocystin mutant constructs
that bind HBx, we also conﬁrmed that hepatocystin inhibited HBx-dependent HBV replication. In conclusion,
we demonstrated for the ﬁrst time that hepatocystin functions as a chaperon-like molecule by accelerating
HBx degradation, and thereby inhibits HBV replication. Our results suggest that inducing hepatocystin may
provide a novel therapeutic approach to control HBV infection.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Hepatitis B virus (HBV) is a noncytopathic, hepatotropic virus that
belongs to the Hepadnaviridae family. HBV infection causes serious
health problems, resulting in acute and chronic hepatitis, cirrhosis
and eventually hepatocellular carcinoma and death [1]. Despite the
existence of an efﬁcient vaccine, more than 400 million people are
carriers of the virus worldwide [2]. Indeed, although therapeuticcology and Center for Cancer
versity School of Medicine, 1
c of Korea. Tel.: +82 2 2080
.V. Open access under CC BY license.nucleos(t)ide analogs and interferons can be used to treat HBV infec-
tion, the number of HBV-infected individuals and HBV-related deaths
continues to increase [3]. Thus, it is of prime importance to under-
stand the mechanisms of HBV–host interactions during HBV infection
to identify novel therapeutic anti-HBV targets.
The HBV X (HBx) protein plays an important role as a transactivator
of viral and many host cell genes. Thus, HBx is thought to play a pivotal
role in viral replication and has been implicated in the development of
hepatocellular carcinoma [4–6]. Most studies have shown that HBx
acts through interactions with cytoplasmic proteins involved in signal-
ing cascades such as the nuclear factor-κB pathway [7,8], the Jak1-STAT
signaling [9], the c-Jun N-terminal kinase pathway [10], and the protein
kinase C pathway [11]. There is also evidence that HBx interacts directly
with a number of nuclear proteins including components of the tran-
scription machinery, particularly with the RPB5 subunit of RNA poly-
merase II [12], transcription factor IIB [13], and the TATA-binding
protein [14] as well asmembers of the CREB/ATF family of transcription
factors [15]. We previously reported that HBx interacts with c-FLIP
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[16]. Furthermore, heat-shock protein (Hsp) family members interact
with HBx, and induce cell death and inhibit replication of HBV [17,18].
However, the functional correlation between host factors and HBx in
HBV pathology remains unclear. Therefore, we performed afﬁnity puri-
ﬁcation and mass spectrometry analysis to search for host factors that
physically interact with HBx. Here we found new HBx binding partners
such as the hepatocystin/80K-H as well as Hsp 70 family members.
Hepatocystin was originally identiﬁed as a protein kinase C sub-
strate [19]. It plays a role as a regulatory subunit of glucosidase II,
which encodes a soluble protein that is rich in glutamic and aspartic
acid with a putative endoplasmic reticulum (ER) retention signal at
the C-terminal region [20] and is downstream of ﬁbroblast growth
factor receptor (FGFR) and keratinocyte growth factor receptor [21].
Hepatocystin interacts with protein kinase Cζ and munc18c to induce
glucose transporter 4 translocation to the plasma membrane [22]. It
has also been identiﬁed as a molecule that interacts with the epithe-
lial Ca2+ channel transient receptor potential cation channel V5, and
regulates channel activity [23]. In addition, its protein function as a
chaperone-like molecule, which prevents ER-associated degradation
of polycystin-2 (TRPP2) was reported [24]. It has been shown to in-
teract with inositol 1,4,5-trisphosphate (IP3) receptors and to regu-
late IP3-induced calcium release [25]. Moreover, hepatocystin has
also been identiﬁed in the genetic background of autosomal domi-
nant polycystic liver disease (PCLD) [26].
In present study, we found a novel function of hepatocystin in
degradation of the HBx protein. Hepatocystin interacted with HBx and
facilitated its degradation via an ubiquitin-independent proteasome
pathway. The association between HBx and hepatocystin inhibited
HBx-dependent HBV replication. We concluded that hepatocystin and
Hsp 70 family members play important roles in the control of HBV rep-
lication based on previous studies that Hsps are implicated in HBV rep-
lication [17,27,28].
2. Materials and methods
2.1. Reagents and plasmids
The following antibodies were used in this study: anti-HA antibody
(Sigma, St. Louis, MO, USA), anti-hepatocystin antibody (Proteintech,
Chicago, IL, USA), anti-Flag M2 antibody (Sigma), anti-actin antibody
(Sigma), anti-HBV surface (HBs) antibody (Abcam, Cambridge, MA,
USA), anti-GFP antibody (Clontech/Takara Bio, Mountain View, CA,
USA), anti-His antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and anti-HBx antibody (BioVender, Heidelberg, Germany). Alexa
Fluor 488 goat anti-rabbit IgG secondary antibody and Alexa ﬂuor 546
goat anti-mouse IgG secondary antibodywere obtained from Invitrogen
(Carlsbad, CA, USA). Anti-mouse and anti-rabbit antibodies conjugated
with horseradishperoxidasewere purchased fromSigma. A proteasome
inhibitor, MG132, was purchased from Calbiochem (La Jolla, CA). The
DAPI nuclear staining reagent was obtained from Molecular Probes
(Eugene, OR, USA). The protein translation inhibitor cycloheximide
(CHX) and lysosome inhibitor NH4Cl was obtained from Sigma. The
HBx-HA and HBx-Flag plasmids, which encode HA-tagged and Flag
tagged HBxwere inserted into the pcDNA3.1 vector (Invitrogen), as de-
scribed previously [29]. HBx deletion mutants (M1, M2, andM3)with a
C-terminal HA-tag were subcloned into the pcDNA 3.1 vector as shown
in Fig. 3A using HBx-HA as a template. The human hepatocystin gene
(Genbank, NM_001001329) was ampliﬁed using the hepatoma Huh-7
cell cDNA library. Full-length wild type hepatocystin and deletion mu-
tants (M1, M2, M3, and M4) with a C-terminal Flag-tag were inserted
into the BamH I/Xba I site of the pcDNA 3.1 vector as shown in Fig. 3C.
The EGFP-N1 plasmid was obtained from Clontech/Takara Bio. The
His-Ub plasmid was constructed by inserting ubiquitin gene fragments
into the pcDNA 3.1 vector. The replication-competent HBV construct,
HBV1.2 (strain ayw) and HBx-deﬁcient HBV construct, HBV1.2 (X−)have been described previously [30] and were kindly provided by
Dr. W.S. Ryu (Yonsei University). All plasmids were prepared and puri-
ﬁed using an endotoxin-free plasmid Midi prep kit (Real Biotech
Corporation, Taipei, Taiwan) and were veriﬁed by DNA sequencing.
The siRNA against hepatocystin (GGAAGAAGUCUCUGGAAGATT) and
the predesigned negative control siRNA against GFP were synthesized
by ST Pharm Co. (Seoul, Korea).
2.2. Cell culture and transfection
The human hepatoma cell lines (HepG2 and Huh-7) were obtained
from the American Type Culture Collection (Manassas, VA, USA).
Huh-7 and HepG2 cells were maintained in DMEM (Gibco, Grand
Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine
serum, penicillin, and streptomycin in a 5% CO2 environment at 37 °C.
Transient transfection or co-transfection was performed at 50–70%
conﬂuency using Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer's instructions. The amount of plasmid DNA was
normalized using an empty vector in all transfection experiments.
2.3. Immunoprecipitation
Cells transiently transfected with the above-mentioned constructs
were lysed with immunoprecipitation (IP) lysis buffer (50 mM Tris–
HCl at pH 7.2, 10 mMNaCl, 1% NP-40 containing protease inhibitor cock-
tails). The lysate was preclariﬁed with Protein G agarose (Sigma) at 4 °C
for 1 h. The clariﬁed lysate was incubated with anti-Flag M2 (Sigma),
anti-hepatocystin (Santa Cruz Biotechnology), anti-HA (Sigma), or
anti-HBx (BioVendor) antibody at 4 °C overnight and then with Protein
G agarose at 4 °C for 4 h. The agarose was washed three times with IP
lysis buffer and boiled. The boiled samples were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed
byWestern blot analysis or mass spectrometry (MS) analysis. Cells were
treated with 25 μM MG132 for 5 h in all IP procedures before cell
harvest.
2.4. In-gel digestion and liquid chromatography-electrospray ionization
tandem MS (LC-ESI-MS/MS) analysis
Each immunoprecipitated protein was separated on 12% SDS-PAGE
followed by staining with Coommasie Blue Staining Reagent. Protein
bands were excised from the gel and subjected to in-gel tryptic diges-
tion according to a procedure described previously [31]. The tryptic
peptides produced by the in-gel tryptic digestion were analyzed by
LTQ-XL MS (Thermo Finnigan, San Jose, CA, USA) coupled with an
Eksigent-Nano-Ultra-UPLC (Eksigent Technologies, Dublin, CA, USA).
Tryptic peptides were loaded on a trap column (100 μm × 1.5 cm;
homemade) packed with C18 regular 5 μm sized resin, after which the
loaded peptides were eluted with a linear gradient from 5 to 40%
solvent B (0.1% formic acid in ACN) for 20 min at a ﬂow rate of
300 nL/min. The eluted peptides were separated on an analytical
column (75 μm × 10 cm; homemade) and the separated peptide ions
were sprayed into the nano-ESI source with a 2.0 kV electrospray volt-
age. All MS/MS spectra were acquired in data-dependent scan mode in
which the threemost abundant spectrawere used from the full MS scan
with 35% normalized collision energy. The repeat duration for dynamic
exclusion was 30 s, repeat count was set to 1, the dynamic exclusion
durationwas set to 180 s, the dynamic exclusion listwas 50, and the ex-
clusion mass width was 1.5 Da.
2.5. Identiﬁcation of proteins and peptides
The acquired MS/MS spectra were generated by Extract_Msn in
Bioworks software (v. 3.3.1) and searched against the NCBI human
RefSeq protein sequence database (date 2012.09.23/34699 protein
entries) with the SEQUEST in BioworksBrowser (v. 3.3.1) using the
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fragment tolerance = 1 Da, oxidation on Met (+16 Da), alkyation on
Cys (+57 Da), number of missed cleavage = 2. The resulting MS/MS
spectra were validated and peptides were identiﬁed using Scaffold 3
(Proteome Software, Portland, OR, USA) which is based on probability
thresholds. We obtained a list of peptides with >95% PeptideProphet
probability and 99% ProteinProphet probability [32].
2.6. Western blot analysis
Cells were harvested in SDS lysis buffer (100 mMTris at pH 8.0, 10%
glycerol, and 1% SDS). Cells were disrupted by boiling for 5 min, and the
lysates were frozen at−80 °C or used immediately. Protein concentra-
tion was quantiﬁed using the bicinchoninic acid method (Pierce,
Rockford, IL, USA). Proteins were boiled in 1× sample buffer (10 mM
Tris–HCl pH 6.8, 1% SDS, 5% glycerol, 0.05% bromophenol blue, and 1%
β-mercaptoethanol) for 5 min and separated on SDS-PAGE. Proteins
were electrotransferred to Immobilon-P membranes (Millipore Corp.,
Bedford, MA, USA) and blotted with the indicated antibodies at 4 °C
overnight in Tris-buffered saline containing 0.05% Tween 20 and 1%
nonfat milk. Membranes were then incubated with horseradish
peroxidase-conjugated antibodies at room temperature for 1 h, and
the signal was detected using enhanced chemiluminescence (Pierce).
The band signal was detected using an LAS-4000 Luminescent Image
Analyzer and analyzed using Multi Gauge software (Fujiﬁlm, Tokyo,
Japan).
2.7. Immunocytochemistry
Huh-7 cells was transfected with the Flag-tagged HBx plasmid or
both HA-tagged HBx and Flag-tagged hepatocystin plasmids. At 48 h
after transfection, the cells were ﬁxed with 3.7% paraformaldehyde
(Sigma) for 15 min at room temperature, rinsed with PBS, and then
permeabilized with a 0.1% Triton X-100 solution for 5 min in a cold
chamber. The cells were incubated with anti-hepatocystin antibody
(1:500 dilution; Proteintech) and anti-Flag antibody (1:500 dilution)
at room temperature for 1 h to investigate colocalization of endogenous
hepatocystinwith the Flag-taggedHBxprotein. The cellswere incubated
with anti-Flag antibody and anti-HA antibody (1:500 dilution) at room
temperature for 1 h to examine the colocalization of cotransfected
Flag-tagged hepatocystin with HA-tagged HBx. After three washes
with PBS, the cells were incubated with Alexa Fluor 488 anti-rabbit
IgG secondary antibody (1:500 dilution) and Alexa Fluor 546 anti-
mouse IgG secondary antibody (1:500 dilution) at room temperature
for 40 min. After three washes with PBS, DAPI solution (1 μg/ml) was
used to stain the nuclei. Fluorescence images were obtained and ana-
lyzed using a Carl Zeiss Axiovert 200 microscopy and software (Carl
Zeiss, Oberkochen, Germany).
2.8. RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR)
Total RNAwas isolated from HepG2 and Huh-7 cells using Trizol re-
agent (Invitrogen) according to the manufacturer's instructions. The
cDNAwas synthesized from4 μg of total RNAwithM-MLV reverse tran-
scriptase (Intron Biotechnology, Daejeon, Korea) using an oligo-dT
primer (Bioneer, Daejeon, Korea) at 37 °C for 1 h. The following PCR
primers were used. For hepatocystin gene ampliﬁcation: 5′-GGC GTC
TCC CTC ACC AAT CAT C-3′ (sense), 5′-TCT CCT CCC GTG CCT TCT TCC
AGT-3′ (anti-sense). For HBx gene ampliﬁcation: 5′-AAA AAG TTG CAT
GGT GCT GGT GAA C-3′ (sense), 5′-GCG CGG GAC GTA CTT TGT-3′
(anti-sense). For GAPDH gene ampliﬁcation: 5′-CGT CTT CAC CAC CAT
GGA GA-3′ (sense), 5′-CGG CCA TCA CGC CAC AGT TT-3′ (antisense).
PCR was performed to amplify hepatocystin and GAPDH: 24 cycles of
denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, and extension
at 72 °C for 60 s. For HBx ampliﬁcation: 35 cycles of denaturation at95 °C for 30 s, annealing at 62 °C for 30 s, and extension at 72 °C for
60 s. The PCR products were examined by electrophoresis on a 1.5%
agarose gel.
2.9. In vivo ubiquitination assay
HepG2 cells were transfected with His-tagged ubiquitin,
HA-tagged HBx, and Flag-tagged hepatocystin expressing plasmids.
The proteasome inhibitor MG132 (25 mM) (Calbiochem) was added
for 5 h before cell harvest. The cells were then lysed with SDS lysis
buffer and boiled for 5 min. The lysates were diluted 1:5 with IP
lysis buffer containing 1 mM DTT (Sigma). Samples were subjected
to IP with anti-HA antibody and analyzed by Western blot using
anti-His antibody.
2.10. Southern blot analysis
Details of the Southern blot assay have been described previously
[33]. Brieﬂy, HBV1.2 or HBV1.2 (X−) was transfected into the
HBx-responsible HepG2 cells using Lipofectamine 2000 reagent. Cells
were harvested by scrapping at 4 days post-transfection, and lysed
with HEPES buffer (10 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA,
and 1% NP-40). The cell lysate was treated for 15 min with DNase I
(1.5 U; Clontech/Takara) and mung bean nuclease (7.5 U; Clontech/
Takara) at 37 °C in reaction buffer (500 mM CaCl2 and 800 mM
MgCl2) to eliminate transfected plasmid DNA. Core particles were pre-
cipitated with polyethylene glycol (PEG) solution (1.2 M NaCl, 60 mM
EDTA, 30% sucrose, 26% PEG 8000). This step was repeated after 2 h in-
cubation on ice, and then the capsid was digested with Proteinase K
(20 mg/ml; Roche Applied Science, Indianapolis, IN) at 37 °C for 2 h
in the presence of SDS. HBVDNAwas extractedwith phenol and precip-
itated with ethanol. Puriﬁed DNA was separated on a 1% agarose gel.
After transfer to a membrane, HBV DNA was detected with a highly
pure randomized HBV probe.
3. Results
3.1. Identiﬁcation of HBV X-interacting proteins by immunoprecipitation
and mass spectrometry
We employed an IP-coupled mass spectrometry (MS) approach to
identify cellular proteins that potentially associate with the HBV X
(HBx) protein in hepatocytes. A plasmid encoding HA-tagged HBx
(HBx) or an empty vector (vector) encoding only the HA sequences
was transfected into cells. Subsequently, HBx and its associated pro-
teins were afﬁnity puriﬁed using anti-HA afﬁnity resin from the cell
lysates. The proteins were resolved on SDS-PAGE and visualized by
Coommasie Blue staining. Fig. 1 shows the SDS-PAGE proﬁles of the
dissociated proteins. Due to the common bands in both vector and
HBx lanes, the HBx protein band was not prominent on SDS-PAGE.
However, we conﬁrmed the HBx protein band using Western blotting
with the anti-HA antibody (data not shown). Two distinct bands were
detected in the HBx lane (Fig. 1A). We excised the two bands from the
vector and the HBx lanes and analyzed them using LC-MS/MS after
in-gel digestion with trypsin. These LC-MS/MS spectra were searched
against the NCBI human RefSeq protein sequence database (date
2012.09.23/34699 protein entries) using the SEQUEST algorithm.
We validated peptides using PeptideProphet with probabilities
>95% and also ProteinProphet probabilities >99% to improve the
conﬁdence of protein identiﬁcation. We identiﬁed 13 proteins from
the two speciﬁc bands in the HBx lane (Table 1). Table 1S provides
detailed information of the identiﬁed proteins. Most of these proteins
are generally involved as molecular chaperones. Although earlier re-
sults showed that chaperone family proteins, such as GrpE/Hsp60,
DnaK/Hsp70, and DnaJ/Hsp40 interact with HBx [17,18,34], we
could not recover the same chaperone family proteins probably due
Fig. 1. Identiﬁcation of HBx-interacting proteins by IP-MS analysis. A) Huh-7cells transfected with pcDNA empty vector (vector) or plasmid encoding HA-tagged HBx (HBx) were
used for immunoprecipitation using anti-HA afﬁnity resin. Eluted proteins were resolved by 12% SDS-PAGE and subjected to Coomassie Blue staining. The predictable HBx band is
denoted with a black arrow. The two bands speciﬁc to the HBx lane are indicated by 1 and 2. The relative mobility of molecular mass markers (in kDa) is shown at left. B) Alignment
of the hepatocystin sequences (NCBI gene no. 48255889) with its peptides (underlined) identiﬁed by MS analysis. C) MS/MS spectra of the precursor ion corresponding to the
ETMVTSTTEPSR peptide of hepatocystin. The b and y ions with corresponding peak values are marked.
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ER chaperones, such as Grp78 and hepatocystin (Fig. 1 and Table 2).
Although these proteins are not exclusively cytoplasmic, Grp78 and
hepatocystin exert various functions outside the ER [21–23,25,35].
We focused our initial efforts on validating the interaction between
HBx and hepatocystin, because hepatocystin is rich in hepatocytes
and we hypothesized that this protein could be an etiological factor
in HBV-related liver disease.3.2. HBx speciﬁcally interacts and colocalizes with hepatocystin in
hepatoma cells
We extracted total cell lysates from Huh-7 cells transfected with a
plasmid encoding HA-tagged HBx, and performed IP using an anti-
hepatocystin antibody followed byWestern blotting with anti-HA an-
tibody to validate the interaction between the HBx and hepatocystin.
HBx was associated with endogenous hepatocystin in the cell lysates
Table 1
Identiﬁcation of proteins interacting with HBx by IP-mass spectrometry.
Band
no.
Accession
no. (GI)
Protein
(Abbreviation)
M.W
(kDa)
Peptide
(Hits)
Sequence
coverage
(%)
1 4758012 Clathrin heavy chain 1 (CLTC) 192 19 17
242246985 Clathrin heavy chain 2
isoform 1 (CLTA)
187 5 3
2 16507237 78 kDa glucose-regulated
protein precursor (GRP78)
72 21 32
24234688 Stress-70 protein, mitochondrial
precursor (HSPA90)
74 18 28
261490659 Caldesmon isoform 3 (CALD1) 66 16 36
5729877 Heat shock cognate 71 kDa
protein isoform 1 (HSPA8)
71 16 24
4503841 X-ray repair cross-
complementing protein 6
(XRCC5)
70 9 22
4758304 Protein disulﬁde-isomerase
A4 precursor (PDIA4)
73 7 16
48255889 Glucosidase 2 subunit beta
isoform 1 precursor
(Hepatocystin/80K-H)
59 5 12
34419635 Heat shock 70 kDa protein
6 (HSPA6)
71 5 10
148613856 Probable ATP-dependent
RNA helicase DDX17
isoform 3 (DDX17)
80 3 4
124256496 Heat shock 70 kDa protein
1-like (HSPA1L)
70 3 6
194248072 Heat shock 70 kDa protein
1 A/1B (HSP1A/1B)
70 3 6
Table 2
Identiﬁcation of hepatocystin as the interacting protein with HBx by IP-mass
spectrometry.
Scan number Position Sequence MH+ Charge Xcorr
5028 207–219 AQQEQELAADAFK 1448.70160 2 4.60
3947 485–496 ETMVTSTTEPSR 1338.62057 2 3.00
5295 282–301 SEALPTDLPAPSAPDLTEPK 2049.03864 2 2.80
5111 197–206 LWEEQLAAAK 1158.61535 2 2.44
4470 125–135 ESLQQMAEVTR 1307.63108 2 2.32
Protein Coverage: 55/525 = 14% by amino acid count, 6232/59141 = 11% by mass
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using anti-HA antibody for HBx IP and anti-hepatocystin for Western
blotting (Fig. 2A middle panel).Fig. 2. HBx interacts and colocalizes with hepatocystin in hepatoma cell. A) Co-IP of HBx
with endogenous hepatocystin. pcDNA3.1 empty vector (vector) or plasmid encoding
HA-tagged HBx were transfected into Huh-7 cells. At 24 h after transfection, cell lysates
(Lysate) were immunoprecipitated with anti-80K-H antibody (upper panel) or anti-HA
antibody (middle panel). Proteins were detected by Western blot (WB) with antibodies
as indicated on the left. Bottom panels show the expression level of each protein in the
cell lysate. B) Co-IP of HA-tagged HBx with Flag-tagged hepatocystin. Indicated plasmids
were transfected into HepG2 cells. At 24 h after transfection, cell lysates were
immunoprecipitated with anti-Flag antibody (upper panel). Proteins were detected by
WB with the antibodies indicated on the left. Cell lysates was probed to conﬁrm expres-
sion levels of the transfected genes (bottom panel). C and D) Co-IP of HBV genome-
driven HBx with endogenous hepatocystin. pcDNA3.1 empty vector (vector) or
HBV1.2mer construct were transfected into Huh-7 cells. At 4 days after transfection, cell
lysates were immunoprecipitated with anti-HBx antibody (C) or anti-hepatocystin anti-
body (D). Proteins were detected byWBwith the antibodies indicated on the left. Cell ly-
sates was probed to conﬁrm the levels of HBs, HBx, and hepatocystin expression (bottom
panel). E) Colocalization of HBxwith endogenous hepatocystin. pcDNA vector (vector) or
plasmid encoding Flag-tagged HBx were transfected into Huh-7 cells. At 24 h after trans-
fection, cells were subjected to immunocytochemistry assay to detect the endogenous
hepatocystin (green) and Flag-tagged HBx (red) using anti-80K-H and anti-Flag antibod-
ies (shown on top). Positions of the nucleus are indicated by DAPI (blue) and merged im-
ages are shown in the right panel. F) Colocalization of HA-tagged HBx with Flag-tagged
hepatocystin. Indicated plasmidswere transfected into Huh-7 cells. At 24 h after transfec-
tion, cells were immunostained with anti-HA (green) and anti-Flag (red) antibodies
(shown on top). Merged images are shown in the right panel.Next, we generated the plasmid encoding Flag-tagged hepatocystin
to conﬁrm the interaction with HBx in cells, because Flag-tagged
hepatocystin can avoid the potential nonspeciﬁc activity of the anti-
hepatocystin antibody. We performed IP with anti-Flag and Western
blotting with the anti-HA antibody using cell lysates extracted from
HepG2 cells cotransfected with plasmids encoding Flag-tagged
hepatocystin and HA-tagged HBx. As shown in Fig. 2B, HBx signiﬁcantly
interacted with hepatocystin when both proteins were coexpressed in
HepG2 cells. These observations suggest that HBx speciﬁcally interacted
with hepatocystin. Although these experiments did not exclude the
possibility that the interaction between HBx and hepatocystin might
be mediated indirectly through other cellular proteins, we were unable
to determine a direct association between HBx and hepatocystin, due to
a failure to purify soluble HBx in recombinant E. coli.
Fig. 3. Domainmapping for the interaction betweenHBx andhepatocystin. A) Schematic presentation of theHBx and its truncatedmutants used in this study. Allmutantswere fusedwith
the HA tag at their C termini. The binding ability of HBx to hepatocystin is shown at right. B) Co-IP of Flag-tagged hepatocystin with HA-tagged HBx mutants. Indicated plasmids were
transfected into HepG2 cells. At 24 h after transfection, cell lysates were immunoprecipitated with anti-Flag antibody (upper panel). Proteins were detected by WB with the indicated
antibodies. Cell lysates were also probed to conﬁrm expression levels of the transfected genes (bottom panel). C) Schematic presentation of the hepatocystin and its truncated mutants
used in this study. The hepatocystin domains for signal peptide (SP), complement-like repeated (CR),mannose 6-phosphate receptor homology (MRH), and C-terminalHDEL ER retention
signal peptide are indicated. All cloneswere fused with the Flag tag at their C termini. The binding ability of hepatocystin with HBx is shown on the right side. D) Co-IP of HA-tagged HBx
with different mutants of Flag-tagged hepatocystin. Indicated plasmids were transfected into HepG2 cells. At 24 h after transfection, cell lysates were immunoprecipitatedwith anti-Flag
antibody (upper panel). Proteins were detected by WB with the indicated antibodies. Cell lysates was probed to conﬁrm the expression levels of transfected genes.
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which is expressed from a replication-competent wild type HBV full
genome, HBV1.2mer [59] was introduced into Huh-7 cells. IP was
performed with anti-HBx antibody or anti-hepatocystin antibody. As
shown in Fig. 2C and D, results demonstrate that hepatocystin inter-
acts with the HBV genome-driven HBx.
We then examined the colocalization of hepatocystin with HBx by
immunocytochemistry using immunoﬂuorescence microscopy. A
plasmid encoding Flag-tagged HBx was transfected into Huh-7 cells
and the nuclei were stained with DAPI. HBx was mainly localized in
the cytoplasm rather than in the nucleus and was typically detected
as granular patterns in the cytoplasm similar to previous reports
[36] (Fig. 2E). The small but signiﬁcant part of HBx was colocalizedFig. 4. Hepatocystin accelerates the degradation of HBx protein through a proteasome-depen
HepG2 (upper panel) and Huh-7 (bottom panel) cells were co-transfected with HA-tagged HB
control for monitoring transfection efﬁciency. At 24 h after transfection, cells were lysed an
hepatocystin on the stability of HBx protein. HepG2 cells were co-transfectedwith HA-tagged H
total RNA isolated from a part of HepG2 cells were analyzed by RT-PCR with primer pairs for h
analyzed by Western blot with the indicated antibodies (bottom panel). C) Hepatocystin accel
and Flag-tagged hepatocystin. At 24 h after transfection, cells were treated with CHX (50 μg/m
tiﬁcation of the remaining HBx levels after normalization to β-actin level using softw
hepatocystin-induced HBx degradation. HepG2 cells were co-transfected with HA-tagged HBx
control for monitoring the transfection efﬁciency. At 24 h after transfection, cells were treate
and analyzed by Western blot with the indicated antibodies. E) Effect of the lysosome inhib
with HA-tagged HBx and Flag-tagged hepatocystin. At 24 h after transfection, cells were treat
analyzed byWB analysis with the indicated antibodies. F) Effect of hepatocystin on HBx ubiqui
were transfected into HepG2 cells. At 48 h after transfection, cells were treatedwith control DM
of 1% SDS followed by boiling for 5 min. The denatured lysates was immunoprecipitated with
anti-His antibody (upper panel). G) Effect of PYR-41, an inhibitor of ubiquitin-activating enzy
co-transfected with HA-tagged HBx and Flag-tagged hepatocystin. At 24 h after transfection
blot using the indicated antibodies. H) Effect of PYR-41 on IκB-α stability as a positive internawith endogenous hepatocystin in the cell (Fig. 2E). We also performed
immunocytochemistry under coexpression of HA-tagged HBx and
Flag-tagged hepatocystin. Ectopic expression of hepatocystin alone
was detected in cytoplasm similar to the intracellular distribution of
endogenous hepatocystin (data not shown). Under coexpression of
HBx and hepatocystin, HBx also colocalized with hepatocystin, but
the colocalized pattern was only shown in a small number of
transfected cells (Fig. 2E). The expression pattern of HBx was altered
to disperse and non-granular distribution through the cytoplasm in
the coexpressing cells (Fig. 2E). This mislocalization of HBx may have
resulted from the association between hepatocystin and HBx.
Taken together, the results suggest that hepatocystin interact with
HBx in hepatocyte during natural course of HBV infection.dent pathway. A) Effect of hepatocystin overexpression on stability of the HBx protein.
x and Flag-tagged hepatocystin. EGFP expression vector was co-transfected as the internal
d analyzed by Western blotting with the indicated antibodies. B) Effect of endogenous
Bx, control GFP siRNA, and hepatocystin siRNA (shown on top). At 48 h after transfection,
epatocystin, HBx, and GAPDH (upper panel). Another part of HepG2 cells were lysed and
erates the turnover of HBx protein. HepG2 cells were co-transfected with HA-tagged HBx
l) for the indicated time intervals, followed by Western blot. The graph shows the quan-
are Multi Gauge (Version 3.2). D) Effect of the proteasome inhibitor MG132 on
and Flag-tagged hepatocystin. EGFP expression vector was co-transfected as the internal
d with control DMSO (−) or 25 mM MG132 (+) for an additional 5 h. Cells were lysed
itor NH4Cl on hepatocystin-induced HBx degradation. HepG2 cells were co-transfected
ed with control PBS (−) or 20 mM NH4Cl (+) for an additional 5 h. Cells were lysed and
tination. Plasmids for His-tagged ubiquitin, HA-tagged HBx, and Flag-tagged hepatocystin
SO (−) or 25 mMMG132 (+) for an additional 5 h. Cells were then lysed in the presence
anti-HA antibody. The immunoprecipitant was then analyzed by Western blot using an
me, on HBx ubiquitination. HepG2 (upper panel) and Huh-7 (bottom panel) cells were
, cells were treated with PYR-41 (25 μg/ml) for an additional 5 h, followed by Western
l control.
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through its MRH domain
IP was carried out using the following deletion mutants of HBx to
further characterize theHBx binding domain involved in the interaction
with hepatocystin: HBx-M1 (51–154), HBx-M2 (1–110), and HBx-M3(deletion of 51–80) (Fig. 3A). A cotransfection study with Flag-tagged
hepatocystin and each of the HA-tagged HBx mutants in HepG2 cells
revealed that all HBx proteins except HBx-M2 (1–110) bound
hepatocystin (Fig. 3B). These data indicate that the HBx carboxyl-
terminal domain (amino acids 110–154) is necessary for binding to
hepatocystin.
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interactionwithHBx, IPwas carried out using the following deletionmu-
tants of hepatocystin: M1 (184–525), M2 (341–525), M3 (419–525),
and M4 (184–400) (Fig. 3C). A coexpression study with HA-tagged
HBx and each of the Flag-tagged hepatocystin mutants in HepG2 cells
showed that all hepatocystin mutants except M4 (184–400) bind to
HBx, and particularly the shortest carboxyl-terminal domain of
hepatocystin (419–525) interacts with HBx (Fig. 3D). The amount of
coprecipitated HBx protein was proportional to the steady state level
of hepatocystin mutants, suggesting that the hepatocystin MRH domain
is necessary for the binding to HBx.Fig. 5. N-terminal domain of hepatocystin is required for degradation of the HBx pro-
tein. A) Hepatocystin-induced degradation of the HBx protein was mediated by the in-
teraction between the proteins. Plasmids for HA-tagged HBx mutants and Flag-tagged
hepatocystin were transfected into HepG2 cells. At 24 h after transfection, the cells
were lysed and analyzed by Western blot with the indicated antibodies. B) Mapping
of the hepatocystin functional domain involved in the stimulation of HBx degradation.
Plasmids for Flag-tagged hepatocystin mutants and HA-tagged HBx were transfected
into HepG2 cells. At 24 h after transfection, cells were lysed and analyzed by Western
blot with the indicated antibodies.3.4. Overexpression of hepatocystin accelerate degradation of the
HBx protein
To test the functional consequences of the hepatocystin interaction
with HBx, we ﬁrst investigated the effect of hepatocystin on HBx ex-
pression levels in transiently transfected HepG2 hepatoma cells. As
shown in Fig. 4A upper panel, hepatocystin expression signiﬁcantly de-
creased HBx protein level but not the GFP protein used as a transfection
control. A similar result was obtained in other Huh-7 hepatoma cells
(Fig. 4A bottom panel). These data indicate that ectopic expression of
hepatocystin decreases the HBx protein level. We knocked-down the
expression of endogenous hepatocystin by using small interfering
RNA (siRNA) to determine whether endogenous hepatocystin affected
the HBx protein level. In cells cotransfected with hepatocystin siRNA
and the HA-tagged HBx expressing vector, hepatocystin knock-down
signiﬁcantly increased HBx protein level, but not HBx mRNA (Fig. 4B).
These results indicate that hepatocystin regulates HBx expression at a
post-transcriptional step.
We determined the half-life of the HBx protein with or with-
out hepatocystin after treatment with CHX which blocks new
protein synthesis to investigate the underlying mechanism of how
hepatocystin regulates levels of HBx protein. As shown in Fig. 4C,
coexpression of hepatocystin greatly reduced stability of the HBx pro-
tein after treatment with CHX compared with that in the control
vector.
To further investigate whether hepatocystin destabilizes the HBx
protein through proteasome activity or lysosome activity, we ob-
served the stability of HBx after treatment of proteasome or lysosome
inhibitor. HepG2 cells cotransfected with HBx and hepatocystin ex-
pressing vector were treated with the proteasome inhibitor MG132,
and then the HBx protein level was measured by Western blot analy-
sis. Repression of HBx by hepatocystin was blocked effectively by the
MG132 treatment (Fig. 4D), no protective effect was observed by the
lysosomal inhibitor NH4Cl (Fig. 4E). These results suggest that
hepatocystin enhances degradation of the HBx protein through a
proteasome-mediated degradation pathway.
We next investigated HBx ubiquitination in cells transfected with
the His-tagged ubiquitin expressing vector to determine whether
hepatocystin-induced HBx degradation is mediated by a ubiquitin-
dependent pathway. We performed IP with the anti-HA antibody and
then a Western blot assay with the anti-His antibody. As shown in
Fig. 4F, overexpression of hepatocystin did not lead to additional en-
hancement of ubiquitinated HBx but it weakly decreased both the
ubiquitinated and total HBx protein levels. To conﬁrm this result, we
investigated the effect of PYR-41 on hepatocystin-induced HBx degra-
dation. PYR-41 is an E1 inhibitor that blocks the activation and subse-
quent transfer of ubiquitin to substrates [37]. Treatment with PYR-41
did not restore the hepatocystin-induced degradation of HBx in
HepG2 cells (Fig. 4G upper panel). A similar result was obtained in an
experiment using Huh-7 cells (Fig. 4G bottom panel). The level of
IκB-α, a well-known ubiquitination substrate, increased as in the posi-
tive control (Fig. 4H). These results suggest that hepatocystin-
mediated destabilization of HBx is ubiquitination independent.3.5. Hepatocystin-induced degradation of the HBx protein is mediated
by a physical interaction and requires the N-terminal CR domain
of hepatocystin
We investigated whether the interaction between hepatocystin
and HBx is involved in the acceleration of HBx degradation. Using
HA-tagged HBx mutants, which show different hepatocystin binding
afﬁnities (Fig. 3B), we determined the stability of each HBx protein
by Western blot analysis. Hepatocystin expression signiﬁcantly re-
pressed the level of full length HBx and the M1 mutant. However,
the level of the M2 HBx mutant, which does not interact with
hepatocystin, was not affected by overexpressing hepatocystin
(Fig. 5A). This result suggests that HBx degradation is mediated by
the physical interaction between hepatocystin and HBx.
To determine the hepatocystin domain responsible for promoting
HBx degradation, different Flag-tagged hepatocystin mutants were
cotransfected with HA-tagged HBx vector into HepG2 cells. As shown
in Fig. 5B, the HBx protein level was signiﬁcantly repressed only by
the expression of full-length hepatocystin, but not by expression of
the N-terminal deletion hepatocystin mutants (M1 and M2). These
data indicate that although the hepatocystin MRH domain is involved
in the interaction with HBx (Fig. 3D), the N-terminal hepatocystin re-
gion containing complement-like repeated (CR) domain is important
for HBx degradation.
It has been well known that HBV replication is independent of HBx
in Huh-7 hepatoma cell line [38]. Thus, we used this cell line to conﬁrm
whether hepatocystin can destabilize HBV genome-driven HBx. As
expected, when HBV1.2mer or HBV1.2 (X−) were introduced into
Huh-7 cells, HBx-negative HBV showed similar replication ability to
the wild type level in Huh-7 cells (Fig. 6A). Under cotransfection with
each hepatocystin expressing vector (full-length, M1, and M2) and
HBV1.2mer, all hepatocystin constructs did not exert an antiviral effect
Fig. 6. Hepatocystin also induces the degradation of HBV genome driven-HBx protein. A) Effect of HBx expression on HBV replication in Huh-7 cell line. Wild type HBV1.2mer and
HBx-negative HBV1.2mer were transfected in HBx-independent Huh7 cells. At 4 days after transfection, HBV DNA replication intermediates were isolated from cytoplasmic nucle-
ocapsids and analyzed by southern blot using a radiolabeled HBV DNA probe. Expression of HBs and HBx antigen were determined by WB analysis. Large HB antigens (LHBs), mid-
dle HB (MHBs), and small HBs (SHBs) are indicated on the right (bottom panel). B) Effect of hepatocystin expression on HBV replication in Huh-7 cell line. Huh-7 cells were
cotransfected with wild type HBV1.2, Flag-tagged full-length hepatocystin, and its mutant plasmids (shown on top). HBV DNA replication and protein expression were determined
as described above. C and D) Effect of hepatocystin expression on destabilization of HBV genome-driven HBx. Huh-7 cells were cotransfected with wild type HBV1.2, Flag-tagged
full-length hepatocystin, and its mutant plasmids (shown on top). At 4 days after transfection, cells were lysed and analyzed by WB with the indicated antibodies.
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was also repressed by full-length hepatocystin, but not by the
N-terminal deletion hepatocystin mutants (Fig. 6C). To further conﬁrm
this effect by hepatocystin, full-length hepatocystin was cotransfected
with HBV1.2mer with different doses into Huh-7 cells. As shown in
Fig. 6D, the levels of HBV genome-driven HBx protein was signiﬁcantly
reduced when coexpressed with hepatocystin in a dose-dependent
manner. These results suggest that hepatocystin can facilitate the deg-
radation of HBx protein during natural course of HBV infection.
3.6. Overexpression of hepatocystin inhibits HBV replication through
interaction with HBx
HBx is essential for HBV gene expression and replication in a mouse
model, primary hepatocytes, and HepG2 cells [4,5]. We showed that
hepatocystin destabilizes HBx proteins. Therefore, we investigated the
role of hepatocystin in HBV replication. A replication-competentwild-typeHBV construct (HBV1.2)was cotransfectedwith hepatocystin
expressing vector into HepG2 cells, and HBV replication and gene ex-
pression were investigated by southern blot and western blot analysis.
Hepatocystin dramatically reduced the replication of wild-type HBV
and HBs expression (Fig. 7A), suggesting that hepatocystin can induce
antiviral response during the natural course of HBV infection. To further
investigate the role of hepatocystin in HBx-dependent HBV replication,
HBx-deﬁcient HBV1.2 (X−) vector was transfected into HepG2 cells,
and the HBV DNA replication and HBs expression were examined. As
shown in Fig. 7B, lack of HBx expression led to a signiﬁcant reduction
in HBV DNA replication and HBs expression, and this reduction was re-
stored to almostwild type HBV levels by coexpression of HBx, similar to
the previous report [5]. Notably, hepatocystin expression decreased the
HBx-assisted HBV replication to the levels of HBx-deﬁcient virus con-
comitant with HBx degradation (Fig. 7B). These results indicate that
hepatocystin-induced HBx degradation results in the inhibition of
HBV replication.
Fig. 7. Hepatocystin inhibits the HBx-dependent HBV replication. A) HepG2 cells were cotransfected with wild type HBV1.2mer and the Flag-tagged hepatocystin plasmid. At 4 days
after transfection, HBV DNA replication intermediates were isolated from cytoplasmic nucleocapsids and analyzed by Southern blot using a radiolabeled HBV DNA probe. The po-
sitions for relaxed circular (RC), double stranded (DS) DNA, and single-stranded (SS) DNA are indicated. Proteins were examined by WB using the indicated antibodies. B) HepG2
cells were cotransfected with HBx-negative HBV1.2 (X−), HA-tagged HBx, and Flag-tagged hepatocystin plasmids. At 4 days after transfection, HBV DNA replication and protein
expression were determined as described above.
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HBV replication, because hepatocystin knockdown enhanced the
level of HBx protein. We performed a Southern blot analysis using
HepG2 cells transfected with hepatocystin siRNA (10 nM) and
wild-type HBV. Downregulation of hepatocystin did not lead to fur-
ther enhancement of wild type HBV replication (Fig. 1S panel A). To
conﬁrm this effect, HBV1.2 (X−) or HBV1.2 was cotransfected with
HBx expressing vector into HepG2 cells. HBx-deﬁcient HBV replica-
tion was signiﬁcantly enhanced by additional HBx expression, how-
ever, no effect was observed in wild type HBV replication despite
additional expression of HBx (Fig. 1S panel B). The results suggest
that the level of genome-driven HBx is sufﬁcient for the maximal
HBV replication in this system (even though endogenous hepatocystin
represses HBx expression), which is consistent with the previous data
[5].
A previous report has demonstrated that HBXIP inhibits HBV repli-
cation by interacting with HBx [48]. As shown in Fig. 7, hepatocystin
inhibited both genome replication and HBs expression. Thus, to inves-
tigatewhether hepatocystin-induced antiviral effect also can bemedi-
ated by interacting with HBx, we examined the HBs expression in
HepG2 cell transfected with HBV1.2mer and hepatocystin deletion
mutants (M1, M2, and M4). The M1 and M2 mutants that are able to
bind with HBx signiﬁcantly reduced HBs expression, whereas M4mu-
tant that does not bind with HBx did not (Fig. 8A). This result suggests
that hepatocystin-induced antiviral effect can be mediated by
interacting with HBx. To conﬁrm the antiviral effect by hepatocystin
mutant, we examined the levels of HBV replication by southern blot
analysis using cells transfected with HBV1.2mer construct. As shown
to Fig. 8B and C, HBV replicationwas dramatically inhibited by expres-
sion of M1 and M2 mutants. Moreover, M1 and M2 mutants also re-
duced the HBx-assisted HBV replication and HBs expression in cells
transfected with HBV1.2 (X−) construct, similar to full-length
hepatocystin (Fig. 8D).
Taken together, the results suggest that hepatocystin exerts the
ant-HBV effect by interacting with HBx, probably by blocking the
HBx function necessary for viral replication.4. Discussion
We identiﬁed hepatocystin as a cellular binding partner with HBx
through using IP-MS analysis. We also demonstrated that the HBx
carboxyl-terminal domain (amino acids 110–154) and the carboxyl-
terminal MRH domain (amino acids, 419–525) of hepatocystin play an
important role in the association of hepatocystin with HBx. Our results
indicate that hepatocystin interact with both the ectopically expressed
and the genome-driven HBx in hepatoma cells, and that this interaction
accelerates HBx degradation, resulting in the inhibition of HBx-
dependent HBV replication.
Hepatocystin was originally described as an ER resident protein.
This protein was identiﬁed as a weak protein kinase C substrate in a
patient with autosomal dominant PCLD [19,26]. Several studies have
demonstrated that hepatocystin is involved in several subcellular
processes such as intracellular calcium sensing, regulation of glucose
metabolism, and a signal adaptor for the FGFR-mediated signaling
pathways [21–23,25]. Hepatocystin functions as a chaperon-like mol-
ecule in the ER lumen, preventing the Herp-mediated ubiquitination
of TRPP2 [24]. In the present study, we ﬁrst found that hepatocystin
functions as a chaperon-like molecule to viral HBx with accelerating
the degradation of HBx. This observation may explain why the level
of association of hepatocystin and HBx was observed only in a small
portion in the immunocytochemistry and IP analyses.
HBx is degraded via ubiquitin-dependent and -independent
proteasome pathways according to the host factor bound to its protein.
For example, p53 and X-linked tumor suppressor (TSPX) facilitate
degradation of the HBx protein via an ubiquitin-dependent pathway
[39,40], and Id-1 and MDM2 destabilize the HBx protein via an
ubiquitin-independent proteasomepathway [41,42]. These studies sug-
gest that these proteins can directly recruit the HBx protein to the 20S
proteasome core particle and facilitate degradation of HBx in an
ubiquitin-independent manner. In the present study, hepatocystin
accelerated the HBx degradation through an ubiquitin-independent
pathway. Thus, we presume that hepatocystin may have a similar
mechanism in the Id-1-mediated degradation of HBx, although we
Fig. 8. Interaction between hepatocystin and HBx is involved in the inhibition of HBx-dependent HBV replication. A) Effect of hepatocystin deletion mutants on expression of HBs
antigen. HepG2 cells were cotransfected with wild type HBV1.2mer and different mutants of Flag-tagged hepatocystin plasmids. At 4 days after transfection, the cells were lysed
and analyzed by WB with the indicated antibodies. B and C) Effect of hepatocystin deletion mutants on HBV replication. HepG2 cells were cotransfected with wild type HBV1.2mer
and different mutants of Flag-tagged hepatocystin plasmids. At 4 days after transfection, HBV DNA replication was analyzed by Southern blot. D) HepG2 cells were cotransfected
with HBx-negative HBV1.2 (X−), HA-tagged HBx, and different mutants of Flag-tagged hepatocystin plasmids. At 4 days after transfection, HBV DNA replication intermediates
were analyzed by Southern blot using a radiolabeled HBV DNA probe. Proteins were examined by WB using the indicated antibodies (bottom panel).
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proteasome subunit (data not shown). HBx has a fundamental property
as both a substrate and potential inhibitor of the proteasome complex
[43]. HBx inhibits proteasome activity by interacting between
C-terminal domain of its protein and the proteasome subunits such as
PSMA7 and PSMC1 [44,45]. Deletion of the C-terminal domain causes
destabilization of the HBx protein [46], suggesting that host factors
interacting with the HBx C-terminus such as hepatocystin may deprive
the function of HBx as a proteasome inhibitor leading to acceleration of
its degradation. However, full-length hepatocystin could destabilize
both ectopically expressed- and HBV genome-driven HBx protein,
whereas the M1 and M2 hepatocystin did not accelerate degradation
of theHBx protein even though they interactedwithHBx. This result in-
dicates that N-terminal CR-domain of hepatocystin is required for
destabilizing the HBx protein. Because the function of CR-domain on
the regulation of protein stability has not been yet reported, we could
not clearly elucidate a role of CR-domain on destabilization of HBx pro-
tein in present study. Therefore, further study for other partners binding
with CR-domainmay need to clearly understand a role of CR-domain on
regulation of protein stability.
HBx is well known to be essential for HBV replication throughout
the life cycle of a virus such as DNA replication and genometranscription in cells and animal model systems [4,5]. Consistent
with previous reports, we also showed that supplement of HBx in
HepG2 cells transfected with HBx-negative virus restored the levels
of capsid-associated HBV DNA as well as expression of the HBs anti-
gen. These results suggest that during the natural course of HBV infec-
tion, some host factors associated with HBx may play an important
role regulating HBV replication. In this study, full-length hepatocystin
inhibited both the replication of HBV DNA and the expression of HBs
antigens through interacting with HBx. Moreover, only the
hepatocystin mutants that interact with HBx inhibited HBV gene ex-
pression and replication in HBx-dependent manner. Recent reports
have suggested that HBx mutants with truncations at the C-terminal
end showed the diminished ability to stimulate HBV replication
[47]. Therefore, binding between C-terminal domain of HBx and
hepatocystin may deprive the function of HBx necessary for the stim-
ulation of HBV replication.
Other report has demonstrated that HBXIP inhibits replication of
HBV by interacting with HBx [48]. In this study, the hepatocystin mu-
tants interacting with HBx effectively inhibited HBV replication in a
HBx-dependent manner. One study reported that mucroporin-M1,
which is artiﬁcially designed by amino acid substitution from a tem-
plate of mucoporin, effectively inhibits HBV replication [49]. Control
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interference has emerged as useful for developing effective anti-
HBV agents [50,51]. Thus, our results demonstrate that these artiﬁcial
hepatocystin constructs may serve as useful candidates for develop-
ing an anti-HBV agent.
HBx can also play multifunctional roles such as regulating intracel-
lular calcium levels, autophagy formation, proteasome activity, and
the cell cycle, which are implicated in development of HCC as well
as regulating HBV replication [6]. The C-terminal domain of HBx has
an important role regulating various transcriptional processes and
maintenance of protein stability [46,52]. However, recent studies
have demonstrated that HBx mutants with C-terminus truncations
are frequently found in HBV-associated tumor tissues, and the trun-
cated HBx mutants may be involved in the development of HCC by
promoting of cell proliferation [53,54]. Therefore, there is possibility
that the complex formed by the interaction between hepatocystin
and the C-terminal domain of HBx is also associated with the devel-
opment of HCC. It has been reported that the levels of hepatocystin
are upregulated in various tumor tissues compared with those in
non-tumor regions [55–57]. Thus, we are now conducting further in-
vestigations into the molecular mechanism of hepatocystin on HBx-
induced hepatocellular carcinogenesis.
Molecular chaperones interact with numerous client proteins for
proper folding of newly synthesized proteins and degradation of
misfolded proteins [58]. Thus, the chaperone molecules interact with
various viral antigens such as HBx during viral replication and regulate
their folding or degradation. In this regard, the molecular chaperones
play an important role as an anti-viral factor during HBV replication
[17,27,28]. For example, overexpression of Hsp40 and Hsp70 proteins
inhibits the replication of HBV by destabilizing HBx [17]. Recent studies
have reported that the protein expression of HSP1B and GRP78 is
upregulated in HBV-infected patient tissues and HepG2.2.15 cells that
are stably transfectedwithHBV. These proteins act as host anti-viral fac-
tors by suppressing HBV replication through activation of the
interferon-signaling pathway [27,28]. Although these previous studies
did not mention the functional correlation between these proteins
and HBx, these chaperone molecules were identiﬁed as host factors
interacting with HBx in our study (Table 1). Therefore, it is plausible
that the antiviral effect caused by these chaperonemolecules is mediat-
ed by functional regulation of the HBx protein. Further investigation is
needed to discover the functional correlation between HBx and the
other host factors identiﬁed in the present study.
5. Conclusions
Our study provides evidence that hepatocystin serves as an antiviral
effecter against HBV. Our study, in part, uncovers the molecular
mechanisms of chaperone-mediated inhibition of HBV replication by
showing that hepatocystin destabilizes the HBx protein through its in-
teraction. Furthermore, we also found that the hepatocystin deletion
mutants will be useful for developing an antiviral agent. Further studies
are necessary to characterize the antiviral process of hepatocystin, and
to investigate the precise role of hepatocystin on HBV pathology such
as hepatocellular carcinogenesis. Our results will aid in the develop-
ment of novel antiviral agents that can overcome resistance to the
current nucleotide analogues.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.026.
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